Galimedix completes phase 1 study with oral small molecule GAL-101
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Alembic receives EIR from USFDA for facility at Panelav
Shantived Hospital generated revenue of around Rs 50 crore in FY2025
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
CRISPR-based detection enables highly specific molecular recognition
Subscribe To Our Newsletter & Stay Updated